My 82 yo mother was stranded in the storm in a flooded car this pm. A kind Spanish speaking couple invited her to their car and took her to their home. I drove 5 hours in rain through high waters and got her. I thanked the couple. They are my heroes today!
In a world pandemic, with nonstop bad news, a little but beautiful flower of cell therapy for MCL blossomed quietly!
Even on April Fools’ day, this is no joke! This is a most exciting milestone for relapsed #mantlecelllymphoma. This is unprecedented great news for our patients!
Today I was notified by the Chief Academic Officer that I have been appointed to be the Puddin Clarke Endowed Professor as of December 1, 2019. I feel much appreciated and extremely honored by my beloved MD Anderson institution!
Last weekend I was invited to a party by a good friend. When I got there, I saw 30 people eating next to each other around tables in the backyard, no masks. They told me all tested negative for COVID. I smiled and left. Cannot put my patients and family at risk.
Congratulations to all patients and their families affected by mantle cell lymphoma! This is a milestone progress!
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma | Gilead Sciences investors.gilead.com/news-releases/…
To all patients and families affected by #mantlecelllymphoma, we now have another magic bullet to treat MCL, this is wonderful news for you, congratulations! Many of you together with a big international team worked on this trial, it is a great team effort!
“Oral pirtobrutinib could be used even after failure of prior BTK inhibitors and will benefit mantle cell lymphoma patients tremendously,” Wang says. “This is a milestone achievement in mantle cell lymphoma therapy.” bit.ly/3JlSdK5@MichaelWangMD#EndCancer [2/2]